ECSP15042897A - Formulaciones orales de deferasirox - Google Patents
Formulaciones orales de deferasiroxInfo
- Publication number
- ECSP15042897A ECSP15042897A ECIEPI201542897A ECPI201542897A ECSP15042897A EC SP15042897 A ECSP15042897 A EC SP15042897A EC IEPI201542897 A ECIEPI201542897 A EC IEPI201542897A EC PI201542897 A ECPI201542897 A EC PI201542897A EC SP15042897 A ECSP15042897 A EC SP15042897A
- Authority
- EC
- Ecuador
- Prior art keywords
- deferasirox
- tablet
- exposure
- present
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un aspecto de la presente invención proporciona una tableta para el tratamiento de enfermedades que causan un exceso de metal, tal como hierro, en un cuerpo humano o animal, o enfermedades causadas por un exceso de metal en un humano que comprende Exjade® TM (deferasirox) de la fórmula I : o una sal farmacéutica aceptable del mismo presente en una cantidad entre 45% y 60% por peso con base en el peso total del comprimido, dicho comprimido tiene una liberación 5 reducida bajo condiciones gástricas y liberación rápida a pH casi neutro o a pH neutro. Típicamente, un fármaco que muestre disolución más rápida tendrá un nivel de exposición mucho mayor cuando se prueba humanos. Sorprendentemente, en el caso actual, las tabletas de Exjade TM (deferasirox) formuladas por tener liberación más lenta mostraron mucho mayor biodisponibilidad y sin efectos en los alimentos cuando se 10 comparan con tabletas dispersables comerciales, que tienen una tasa de disolución más rápida, pero que exhiben significativamente niveles de exposición más bajos. Las características de los comprimidos y sachets tragables (ingeribles, administrables por vía oral), tales como su tiempo de desintegración y disolución son necesarias únicamente para llegar a los niveles de exposición previstos. 15 Otro aspecto de la presente invención proporciona un comprimido recubierto que comprende (a) deferasirox o una sal farmaceuticamente aceptable del mismo, y (b) al menos un excipiente farmaceuticamente aceptable adecuado
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361774893P | 2013-03-08 | 2013-03-08 | |
| US201361824435P | 2013-05-17 | 2013-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15042897A true ECSP15042897A (es) | 2019-03-29 |
Family
ID=50288212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201542897A ECSP15042897A (es) | 2013-03-08 | 2015-10-08 | Formulaciones orales de deferasirox |
Country Status (42)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3124018B2 (en) | 2013-03-08 | 2024-04-24 | Novartis Ag | Oral formulations of deferasirox |
| US9866684B2 (en) * | 2015-02-16 | 2018-01-09 | Microsoft Technology Licensing, Llc | Process for real-time data exchange between users on a phone call |
| WO2016167729A1 (en) * | 2015-04-16 | 2016-10-20 | Öğün Yusuf Toktamiş | Dispersible tablets comprising deferasirox |
| EP3310354B1 (en) * | 2015-06-17 | 2026-02-25 | AustinPx, LLC | Improved formulations of deferasirox and methods of making the same |
| US20190091204A1 (en) | 2016-03-17 | 2019-03-28 | Lupin Limited | Compositions of deferasirox |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2018007956A1 (en) * | 2016-07-05 | 2018-01-11 | Jubilant Generics Limited | Immediate release pharmaceutical composition of iron chelating agents |
| EP3518904A1 (en) | 2016-09-30 | 2019-08-07 | Synthon B.V. | Pharmaceutical composition comprising deferasirox |
| CZ2017255A3 (cs) | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
| TR201707764A2 (tr) * | 2017-05-29 | 2018-12-21 | Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi | Deferasiroksun bölünebilir tablet formları. |
| WO2019108156A1 (en) * | 2017-11-28 | 2019-06-06 | Biofarma Ilac Sanayi Ve Ticaret A.S. | A scored tablet formulation comprising deferasirox in a film tablet form |
| KR20200113116A (ko) | 2019-03-22 | 2020-10-06 | 주식회사 한국팜비오 | 데페라시록스를 포함하는 필름코팅정제 |
| EP3854385A1 (en) * | 2020-01-27 | 2021-07-28 | ROS Therapeutics ApS | Methotrexate dosage form |
| WO2022186809A1 (en) * | 2021-03-05 | 2022-09-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | The film coated tablet comprising deferasirox |
| CN115154428B (zh) * | 2022-09-06 | 2023-01-10 | 上海奥科达医药科技股份有限公司 | 一种地拉罗司药物组合物及其制备方法 |
| WO2025242589A1 (en) | 2024-05-21 | 2025-11-27 | Chiesi Farmaceutici S.P.A. | Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| GB0223978D0 (en) | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
| GB0408078D0 (en) * | 2004-04-08 | 2004-05-12 | Novartis Ag | Organic compounds |
| KR20070022243A (ko) * | 2004-04-08 | 2007-02-26 | 노파르티스 아게 | 데페라시록스 분산성 정제 |
| CA2625112A1 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Dispersible tablets comprising deferasirox |
| EP2062572A1 (en) † | 2007-11-19 | 2009-05-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions |
| WO2009106824A2 (en) | 2008-02-25 | 2009-09-03 | Cipla Limited | Pharmaceutical formulations |
| WO2009130604A2 (en) * | 2008-04-21 | 2009-10-29 | Actavis Group Ptc Ehf | Solid state forms of deferasirox salts and process for the preparation thereof |
| WO2010035282A1 (en) | 2008-09-24 | 2010-04-01 | Matrix Laboratories Limited | Pharmaceutical compositions comprising deferasirox |
| WO2010143006A1 (en) * | 2009-06-10 | 2010-12-16 | Carlo Ghisalberti | Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease |
| EA201390079A1 (ru) * | 2010-07-08 | 2013-09-30 | Рациофарм Гмбх | Пероральная лекарственная форма деферазирокса |
| MY165826A (en) | 2010-10-01 | 2018-05-17 | Cipla Ltd | Pharmaceutical composition |
| EP3124018B2 (en) | 2013-03-08 | 2024-04-24 | Novartis Ag | Oral formulations of deferasirox |
| US20190091204A1 (en) | 2016-03-17 | 2019-03-28 | Lupin Limited | Compositions of deferasirox |
-
2014
- 2014-03-06 EP EP16188627.0A patent/EP3124018B2/en active Active
- 2014-03-06 HU HUE16188627A patent/HUE036921T2/hu unknown
- 2014-03-06 JO JOP/2014/0075A patent/JO3570B1/ar active
- 2014-03-06 DK DK14710654.6T patent/DK2964202T3/en active
- 2014-03-06 EA EA201591665A patent/EA031719B1/ru not_active IP Right Cessation
- 2014-03-06 RS RS20180167A patent/RS56890B1/sr unknown
- 2014-03-06 WO PCT/IB2014/059494 patent/WO2014136079A1/en not_active Ceased
- 2014-03-06 PT PT14710654T patent/PT2964202T/pt unknown
- 2014-03-06 NZ NZ711179A patent/NZ711179A/en unknown
- 2014-03-06 JP JP2015560837A patent/JP6434429B2/ja active Active
- 2014-03-06 ME MEP-2019-30A patent/ME03297B/me unknown
- 2014-03-06 CA CA2890465A patent/CA2890465A1/en not_active Abandoned
- 2014-03-06 SI SI201431064T patent/SI2964202T1/sl unknown
- 2014-03-06 AU AU2014224198A patent/AU2014224198B2/en active Active
- 2014-03-06 CU CUP2015000110A patent/CU24348B1/es unknown
- 2014-03-06 HU HUE14710654A patent/HUE041224T2/hu unknown
- 2014-03-06 UY UY0001035367A patent/UY35367A/es not_active Application Discontinuation
- 2014-03-06 TW TW107112193A patent/TWI686215B/zh active
- 2014-03-06 LT LTEP14710654.6T patent/LT2964202T/lt unknown
- 2014-03-06 PL PL14710654T patent/PL2964202T3/pl unknown
- 2014-03-06 BR BR112015021254A patent/BR112015021254A2/pt not_active IP Right Cessation
- 2014-03-06 PT PT161886270T patent/PT3124018T/pt unknown
- 2014-03-06 CN CN201480012815.XA patent/CN105025886B/zh active Active
- 2014-03-06 RS RS20190142A patent/RS58317B1/sr unknown
- 2014-03-06 MX MX2015011962A patent/MX361055B/es active IP Right Grant
- 2014-03-06 GE GEAP201713929A patent/GEP20186810B/en unknown
- 2014-03-06 DK DK16188627.0T patent/DK3124018T3/en active
- 2014-03-06 KR KR1020157027470A patent/KR101925671B1/ko active Active
- 2014-03-06 HR HRP20190173TT patent/HRP20190173T1/hr unknown
- 2014-03-06 SI SI201430621T patent/SI3124018T1/en unknown
- 2014-03-06 PE PE2015001870A patent/PE20151600A1/es unknown
- 2014-03-06 AP AP2015008668A patent/AP2015008668A0/xx unknown
- 2014-03-06 KR KR1020177010591A patent/KR20170045391A/ko not_active Withdrawn
- 2014-03-06 TW TW103107731A patent/TWI625136B/zh active
- 2014-03-06 LT LTEP16188627.0T patent/LT3124018T/lt unknown
- 2014-03-06 MY MYPI2015702695A patent/MY170303A/en unknown
- 2014-03-06 ES ES16188627T patent/ES2663135T5/es active Active
- 2014-03-06 SG SG11201506491RA patent/SG11201506491RA/en unknown
- 2014-03-06 EP EP14710654.6A patent/EP2964202B2/en active Active
- 2014-03-06 SG SG10201807204YA patent/SG10201807204YA/en unknown
- 2014-03-06 PL PL16188627T patent/PL3124018T3/pl unknown
- 2014-03-06 ES ES14710654T patent/ES2708955T5/es active Active
- 2014-03-06 US US14/198,872 patent/US9283209B2/en active Active
-
2015
- 2015-05-12 SA SA515360425A patent/SA515360425B1/ar unknown
- 2015-08-20 ZA ZA2015/06060A patent/ZA201506060B/en unknown
- 2015-08-24 IL IL240797A patent/IL240797B/en unknown
- 2015-09-04 TN TN2015000393A patent/TN2015000393A1/en unknown
- 2015-09-07 CL CL2015002495A patent/CL2015002495A1/es unknown
- 2015-09-07 PH PH12015501981A patent/PH12015501981B1/en unknown
- 2015-09-07 NI NI201500126A patent/NI201500126A/es unknown
- 2015-09-08 CR CR20150467A patent/CR20150467A/es unknown
- 2015-09-08 DO DO2015000220A patent/DOP2015000220A/es unknown
- 2015-10-08 EC ECIEPI201542897A patent/ECSP15042897A/es unknown
-
2016
- 2016-02-05 US US15/017,084 patent/US20160220493A1/en not_active Abandoned
-
2017
- 2017-06-08 AU AU2017203897A patent/AU2017203897B2/en active Active
- 2017-06-16 US US15/625,863 patent/US20170290811A1/en not_active Abandoned
-
2018
- 2018-03-06 HR HRP20180387TT patent/HRP20180387T1/hr unknown
- 2018-03-12 CY CY20181100302T patent/CY1120021T1/el unknown
- 2018-03-23 US US15/934,595 patent/US20180221285A1/en not_active Abandoned
- 2018-05-24 JP JP2018099612A patent/JP6739470B2/ja active Active
-
2019
- 2019-01-31 CY CY20191100143T patent/CY1121315T1/el unknown
-
2020
- 2020-06-08 JP JP2020099402A patent/JP2020180123A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15042897A (es) | Formulaciones orales de deferasirox | |
| CY1121107T1 (el) | Φαρμακοτεχνικες μορφες δισκιων αμεσης απελευθερωσης | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| JP2015038135A5 (es) | ||
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| NZ631100A (en) | Soft chewable pharmaceutical products | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| IN2015DN04311A (es) | ||
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| BR112012029170A2 (pt) | fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo | |
| CR20120084A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| JP2014221827A5 (es) | ||
| MX2019001596A (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| MX2015006011A (es) | Pastilla medicinal a base de ibuprofeno sodico dihidratado. | |
| UY33468A (es) | Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal | |
| MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib |